1-9 of 9
Chun Yew Fong, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Eliza A Hawkes, FRACP,MDMBBS, Geoffrey Chong, MD, Charmaine Smith, Sze-Ting Lee, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, MBBS, Niles Elizabeth Nelson, BSc, MBBS, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, MBBS, MD FRACP, FRCPA, Colm Keane, MD, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Kate Manos, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-136024
Published: 2020
Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 55–57.
https://doi.org/10.1182/blood-2020-139492
Published: 2020
Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2662.
https://doi.org/10.1182/blood-2019-125966
Published: 2019
Journal Articles

Rapid Elimination of NPM1 Mutant Measurable Residual Disease (MRD) Using Low Intensity Venetoclax-Based Combinations in Acute Myeloid Leukemia (AML)

Ing S Tiong, MBChB,FRACP,FRCPA, Richard Dillon, MA, PhD MRCP, FRCPath, Adam Ivey, BSc, MSc, PhD, Tse-Chieh Teh, MBBS,PhDFRACP, FRCPA, Catherine Vassili, RN,MN, Vanessa Roma Donati, RN, David Taussig, PhD MRCP, FRCPath, Nicola Potter, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Mikel Valganon, PhD, Nigel H. Russell, MD, Kavita Raj, MD PhD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Andrew Grigg, Steven Knapper, DM, Andrew H. Wei, PhD FRACP, FRCPA, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 2648.
https://doi.org/10.1182/blood-2019-123899
Published: 2019
Journal Articles

A Phase 3 Randomized Study (PRIMULA) of the Epigenetic Combination of Pracinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, with Azacitidine (AZA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Intensive Chemotherapy (IC)

Guillermo Garcia-Manero, MD, Maciej Kaźmierczak, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Adriano Venditti, Silvia Mappa, MD, Riccardo Spezia, Lionel Ades, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2652.
https://doi.org/10.1182/blood-2019-125924
Published: 2019
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 568.
https://doi.org/10.1182/blood-2019-124437
Published: 2019
Journal Articles

Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT study)

Andrew H Wei, MBBS,PhD, Chong Chyn Chua, MBBS, BMedSc, Ing S Tiong, MBChB, Chun Yew Fong, MBBS,FRACP,FRCPA, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Sarah Macraild, Jessica M Salmon, PhD, Adam Ivey, BSc, MSc, PhD, John Nguyen, Flora Yuen, BBiomedSc, Richard Hall, Shaun Fleming, Stefan K. Bohlander, MD, John Reynolds, PhD, Andrew W. Roberts, MBBS, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 333.
https://doi.org/10.1182/blood-2018-99-114243
Published: 2018
Journal Articles

Modelling Resistance to Emerging Epigenetic Therapies

Chun Yew Fong, MBBS FRACP FRCPA, Omer Gilan, PhD, Enid Lam, PhD, Alan Rubin, PhD, Jessica Morison, PhD, George Giotopoulos, PhD, Kym Stanley, Ftouni Sarah, MSc, Dean Tyler, Dave Lugo, Philip Jeffrey, Richard Gregory, Jaring Schreuder, Shalin Naik, PhD, Tony Kouzarides, PhD, Brian Huntly, MD PhD, Ricky W Johnstone, PhD, Rab K Prinjha, Anthony Papenfuss, PhD, Mark A Dawson, MBBS FRACP FRCPA PhD
Journal: Blood
Blood (2014) 124 (21): 3546.
https://doi.org/10.1182/blood.V124.21.3546.3546
Published: 2014
Journal Articles

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Chun Yew Fong, MBBS, George Grigoriadis, MBBS, PhD, BSc, Jay Hocking, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Hatem H. Salem, MD, FRACP, FRCPA, Andrew Spencer, MD, Andrew H Wei, MBBS, PhD
Journal: Blood
Blood (2011) 118 (21): 3631.
https://doi.org/10.1182/blood.V118.21.3631.3631
Published: 2011